Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Genentech submits ACTEMRA sBLA to FDA

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for ACTEMRA® (tocilizumab) for the prevention of structural joint damage (as assessed by radiograph) and improvement in physical function in adults with moderately to severely active rheumatoid arthritis (RA).

17 Mar 2010

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

The Fonds de la recherche en santé du Québec in partnership with the Ministère de la Santé et des Services sociaux and Pfizer Canada, is announcing the creation of the Pfizer-FRSQ-MSSS Chronic Disease Fund. Established with an investment of $5 million from Pfizer Canada, this research grant program, coordinated by the FRSQ, is open to Quebec-based researchers who work in collaboration with health professionals.

17 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Iverson Genetic Diagnostics to conduct WARFARIN clinical study

Iverson Genetic Diagnostics, Inc. today announced that they will conduct a WARFARIN clinical study to assess the efficacy of gene-based testing prior to initiating warfarin anticoagulation therapy to reduce the incidence of bleeding and thromboembolic events.

16 Mar 2010

Lexicon Pharmaceuticals announces pricing of public offering and concurrent private placement of common stock

Lexicon Pharmaceuticals, Inc. today announced the pricing of a public offering and concurrent private placement of its common stock in which the aggregate net proceeds to Lexicon will be approximately $165.0 million. The public offering consists of 87,717,391 shares of its common stock at a public offering price of $1.15 per share.

16 Mar 2010

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

Makers of a new liquid natural supplement formulation of Cetyl-Myristoleate (CMO) are seeking osteoarthritis and fibromyalgia patients for a pilot study in Phoenix beginning Monday, April 12, 2010.

16 Mar 2010

Endobronchial ultrasound: More precise and less invasive than other lung cancer staging methods

A new technique being used by thoracic surgeons at Rush University Medical Center offers a more precise, less invasive and more versatile way of assessing a patient's lymph nodes and chest tumors to determine if lung cancer has spread to other parts of the body.

16 Mar 2010

Arthritis drug could be useful for treating patients with type 2 diabetes

Clinical studies of a generic drug called salsalate, widely prescribed for arthritis, now provide early promising results that it may be useful for the treatment of patients with type 2 diabetes as well.

16 Mar 2010

EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin

Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non-major (CRNM) bleeds compared to dose-adjusted warfarin.

16 Mar 2010

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers.

16 Mar 2010

CPF, PFF applaud PF patients' efforts to plead with FDA Advisory Panel regarding lack of treatment options

The Coalition for Pulmonary Fibrosis and the Pulmonary Fibrosis Foundation are applauding the efforts of Pulmonary Fibrosis (PF) patients and family members for their work to convey to the FDA and an FDA Advisory Committee the sense of urgency and desperation regarding the disease and the lack of treatment options.

15 Mar 2010

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

As part of the Salmonella Montevideo investigation, the Food and Drug Administration has been actively investigating the supply chain of black and red pepper supplied to Daniele International Inc., Pascoag, R.I.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.

15 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

Ligand Pharmaceuticals Incorporated today announced that GlaxoSmithKline was granted marketing authorization from the European Commission for Revolade® (eltrombopag) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

Study finds implant durability not affected by high-impact sports participation

Total knee arthroplasty (TKA) patients may be able to participate in high-impact sports without increasing risk of early implant failure, according to a new study presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

15 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Childhood obesity: Genetic variation could be a factor

Increasing childhood obesity has worried governments and public health advisers in many countries. But a study of 300 children with severe obesity by the University of Cambridge and the Wellcome Trust Sanger Institute, suggest the problem may be more complicated than simply bad diet, overeating, or lack of exercise.

12 Mar 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Genentech submits ACTEMRA sBLA to FDA

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Iverson Genetic Diagnostics to conduct WARFARIN clinical study

Lexicon Pharmaceuticals announces pricing of public offering and concurrent private placement of common stock

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

Endobronchial ultrasound: More precise and less invasive than other lung cancer staging methods

Arthritis drug could be useful for treating patients with type 2 diabetes

EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

CPF, PFF applaud PF patients' efforts to plead with FDA Advisory Panel regarding lack of treatment options

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Nanoparticles provide a targeted version of photothermal therapy for cancer

Ligand Pharmaceuticals: GSK granted marketing authorization from EC for Revolade

New study finds green tea extract may prevent Alzheimer's disease and dementia

Study finds implant durability not affected by high-impact sports participation

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Childhood obesity: Genetic variation could be a factor

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in